Pegvaliase

Pegvaliase is a medication used in the treatment of phenylketonuria, a rare genetic disorder. It is an enzyme therapy that helps to break down phenylalanine in the body, which is typically difficult for individuals with phenylketonuria to do.

Overview

Pegvaliase, sold under the brand name Palynziq, is a enzyme substitution therapy that is used to lower blood phenylalanine levels in adults with phenylketonuria who have uncontrolled blood phenylalanine levels on current treatment.

Mechanism of Action

Pegvaliase works by substituting the activity of phenylalanine hydroxylase (PAH), an enzyme that is deficient in people with phenylketonuria. This enzyme is responsible for the conversion of phenylalanine to tyrosine, a process that is impaired in individuals with phenylketonuria.

Side Effects

Common side effects of pegvaliase include injection site reactions, joint pain, hypersensitivity reactions, headache, generalized skin reactions lasting at least 14 days, pruritus (itching), nausea, dizziness, abdominal pain, throat pain, fatigue, vomiting, cough and diarrhea.

Precautions

Before starting treatment with pegvaliase, it is important to discuss any existing medical conditions or allergies with your healthcare provider. It is also important to discuss any other medications or supplements you are currently taking, as pegvaliase may interact with them.

See Also

• Phenylketonuria
• Enzyme substitution therapy
• Phenylalanine
• Tyrosine

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia